Case Reports in Oncology最新文献

{"title":"Erratum.","authors":"","doi":"10.1159/000543459","DOIUrl":"https://doi.org/10.1159/000543459","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000542201.].</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"246"},"PeriodicalIF":0.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Systemic Chemotherapy Including Immune Checkpoint Inhibitors for Patients with Tumor-Associated Dermatomyositis.","authors":"Yukino Kawamura, Akihiko Shimomura, Tomoko Taniyama, Hoshie Hirai, Kazuki Hashimoto, Yayoi Honda, Dai Kitagawa, Hiroshi Kaneko, Chikako Shimizu","doi":"10.1159/000543579","DOIUrl":"10.1159/000543579","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs), used in cancer immunotherapy, enhance the immune system's ability to attack cancer cells. However, this activation can lead to severe immune-associated adverse events due to overactivation. In autoimmune diseases, the immune system mistakenly targets the body's tissues, producing autoantibodies that cause inflammation and tissue damage. Despite the increasing use of ICIs, limited information exists on their effects and potential harms in patients with active autoimmune diseases, making it challenging to predict outcomes and manage risks for these patients.</p><p><strong>Case presentation: </strong>We report a case of a patient with breast cancer presenting with a rash and muscle weakness. The simultaneous onset of these symptoms, along with the rapid growth of the breast tumor, led to a diagnosis of tumor-associated dermatomyositis (DM). The patient presented with locally advanced triple-negative breast cancer and received preoperative chemotherapy, including ICIs.</p><p><strong>Conclusion: </strong>The administration of preoperative chemotherapy, including ICIs, to a patient with breast cancer and tumor-associated DM was found to be a safe and effective treatment approach. There is a need to better understand the interplay between ICIs and autoimmune diseases and to develop safe and effective treatment strategies for this unique patient population.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"231-238"},"PeriodicalIF":0.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Uterine Serous Carcinoma: Importance of Early Detection and Comprehensive Treatment in Postmenopausal Women.","authors":"Amjad Hijazi, Gieth Alahdab, Aland Oso, Ahmad Abboud, Safa K Salman","doi":"10.1159/000542359","DOIUrl":"10.1159/000542359","url":null,"abstract":"<p><strong>Introduction: </strong>Uterine serous carcinoma (USC) is an uncommon but highly aggressive subtype of endometrial cancer, constituting approximately 10% of all endometrial carcinoma cases. Due to its aggressive nature, it is often diagnosed at an advanced stage, with a significant proportion of patients presenting with metastasis.</p><p><strong>Case presentation: </strong>This report deals with a case of a 75-year-old postmenopausal female with a history of obesity and hypertension, presenting with abnormal vaginal bleeding over 2 years. Her obstetric history included three cesarean sections, and she had not undergone a speculum examination for 35 years. Transvaginal ultrasound revealed a heterogeneous structure with cystic changes nearly filling the uterine cavity, suggestive of an intrauterine polyp. Dilation and curettage under general anesthesia disclosed that the uterine cavity is filled with gray, soft endometrial material. Histopathological examination confirmed the diagnosis of serous papillary carcinoma of the endometrium. Subsequent imaging was unremarkable for distal metastasis. The patient underwent an abdominal total hysterectomy with bilateral adnexectomy and pelvic lymphonodectomy. Histopathology indicated high-grade papillary serous adenocarcinoma with minimal myometrial invasion and metastasis in 3 out of 10 regional lymph nodes. Postoperatively, she received 25 sessions of radiotherapy and four doses of chemotherapy with paclitaxel and carboplatin. Nine months post-surgery, the patient remains in good health and adheres to a strict monitoring protocol. This case emphasizes the necessity of comprehensive diagnostic evaluations and aggressive treatment in postmenopausal women presenting with vaginal bleeding.</p><p><strong>Conclusion: </strong>Despite its typically poor prognosis, early diagnosis and treatment of USC can lead to favorable outcomes. This case underscores the importance of timely intervention in managing postmenopausal vaginal bleeding, particularly in the context of potential malignancies.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"174-180"},"PeriodicalIF":0.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An ACTH-Producing Neuroendocrine Tumor: Clinical Course of Multidisciplinary Therapy Including Peptide Receptor Radionuclide Therapy - A Case Report.","authors":"Tomonobu Koizumi, Ai Sato, Kohei Kitajima, Masanori Yamazaki, Sana Kanazawa, Tsuyoshi Notake, Yoshinori Sato, Shota Kobayashi, Mai Iwaya, Takako Umeda, Mitsuhisa Komatsu","doi":"10.1159/000543177","DOIUrl":"10.1159/000543177","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical experiences of peptide receptor radionuclide therapy (PRRT) in patients with adrenocorticotropic hormone (ACTH) producing neuroendocrine tumor (NET) were extremely rare.</p><p><strong>Case presentation: </strong>A 60-year-old woman with hypertension, lower-extremity edema, hypoalbuminemia, hypokalemia, and multiple hepatic tumors was hospitalized for further examination and treatment. Endocrine testing detected excessive levels of ACTH and cortisol in her blood. Pathohistological examination revealed the hepatic lesions to be ACTH-positive grade 2 NETs (G2). A diagnosis of ectopic ACTH-producing NET was made. The patient was initially treated with the 11-hydroxylase inhibitor, metyrapone, to control hypercortisolemia and the long-acting somatostatin analog, lanreotide. Simultaneously, everolimus was continued for about 1 year. Subsequently, hepatic tumors were surgically resected, leading to successful and rapid normalization of ACTH secretion and resolution of hypercortisolemia. However, the disease relapsed and presented with multiple hepatic masses and increased ACTH 18 months after surgery. As sunitinib and subsequent streptozocin chemotherapy failed to control the disease, PRRT with ¹⁷⁷Lu-DOTATATE was performed. ACTH levels increased after initiation of PRRT, and clinical manifestations, such as pigmentation, hypertension, and hyperglycemia, were remarkable. The patient was treated with antihypertensive and antidiabetic agents, and required an increased dose of metyrapone and addition of the cortisol biosynthesis inhibitor, osilodrostat. After four cycles of PRRT, the hepatic tumors showed a remarkable reduction in size with normalization of ACTH level and withdrawal of cortisol synthesis inhibitors.</p><p><strong>Conclusion: </strong>Although PRRT was effective, we should consider the occurrence of hormonal crisis during the therapy. Due to the rarity and complexity of hormone-producing tumors, cooperation between medical oncologists and endocrinologists is important for patient management.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"181-189"},"PeriodicalIF":0.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Cell Lung Cancer with Dual Paraneoplastic Syndromes: A Case Report.","authors":"Jingjing Song, Linlin Fan","doi":"10.1159/000542763","DOIUrl":"10.1159/000542763","url":null,"abstract":"<p><strong>Introduction: </strong>Paraneoplastic syndromes are common in cancers such as lung, breast, and ovarian cancers. Still, the dual paraneoplastic syndromes of ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) and raised pancreatic enzymes at the same time are rare. EAS is due to the production of ACTH by tumors other than the pituitary gland, which stimulates the hyperplasia of the adrenal cortex to secrete excessive corticosteroids, most commonly in lung cancer. Elevated pancreatic enzymes are associated with ectopic secretion from lung cancer. Clinically, some patients with small cell lung cancer (SCLC) have atypical early clinical manifestations and may present with paraneoplastic syndrome as the first symptom.</p><p><strong>Case report: </strong>This article describes a case of a 45-year-old male patient who was admitted to the hospital with \"intermittent mild edema of both lower extremities for more than 1 month\" and showed persistent low potassium without diuretic drugs and with abnormally high blood amylase and blood lipase in the exclusion of pancreatitis. The persistent low potassium was caused by unusually high cortisol levels in patients with EAS that result from large amounts of cortisol secretion. Pancreatitis was excluded, and he was finally diagnosed with extensive-stage SCLC after bronchoscopic biopsy and histopathological confirmation. The patient presented with dual paraneoplastic syndromes of SCLC combined with EAS, high pancreatic enzymes, dual metastases, high malignancy, loss of surgical opportunities, and poor prognosis. The patient died at the end of the first cycle of chemotherapy due to the combination of IV degree of myelosuppression, metabolic alkalosis, severe infection, respiratory failure, and the rapid deterioration of his condition.</p><p><strong>Conclusion: </strong>Most of the clinical manifestations of lung cancer with paraneoplastic syndrome as the first symptom lack specificity. The paraneoplastic syndrome of lung cancer can appear in all stages of the disease, and if it appears before the diagnosis of lung cancer, it is of some significance in guiding the diagnosis of lung cancer. Meanwhile, when pancreatic lesions are excluded, we should consider malignancy-related hyperpancreatinemia.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"159-168"},"PeriodicalIF":0.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report.","authors":"Ryota Tatsuhige, Keiki Yokoo, Taku Hatakeyama, Takayuki Nagao, Satoshi Ota, Gen Yamada, Hirofumi Chiba","doi":"10.1159/000543251","DOIUrl":"10.1159/000543251","url":null,"abstract":"<p><strong>Introduction: </strong>Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). Whereas durvalumab is an immune-checkpoint inhibitor (ICI), which has been administered to those with unresectable stage III NSCLC. The efficacy and safety of sequential treatment in patients with METex14 are unclear. Reports have suggested that the administration of tyrosine kinase inhibitors after ICIs could potentially increase the incidence of drug-induced lung injury.</p><p><strong>Case presentation: </strong>A 76-year-old female patient was diagnosed NSCLC harbouring METex14 with clinical stage IIIA (cT2aN2M0). Chemoradiotherapy and consolidation therapy with durvalumab were initiated to achieve a cure. Durvalumab was discontinued due to interstitial lung disease (ILD). After systemic disease progression was observed, tepotinib was initiated 7 weeks after the last dose of durvalumab. She developed ILD due to the sequential treatment of tepotinib after durvalumab.</p><p><strong>Conclusion: </strong>It is unclear whether tepotinib is safe in patients with METex14 after durvalumab administration. Considering the residual period of ICIs in the body, caution should be exercised when initiating molecular-targeted drugs after ICI administration in patients with NSCLC with METex14.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"144-150"},"PeriodicalIF":0.7,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Presentation of a Rare Case of Immunotherapy Combination-Induced Encephalitis: A Case Report.","authors":"Pamela Sfeir, Francois Kamar","doi":"10.1159/000543215","DOIUrl":"10.1159/000543215","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors have revolutionized cancer treatment owing to their ability to activate cellular immune checkpoint pathways and mediate an antitumor activity. Due to their immunological actions, immune-related adverse events (irAEs) have become a concern. Neurological adverse events are rarely seen whether in the central or peripheral nervous system and can be potentially life-threatening. We present a rare case of occipital encephalitis following dual immunotherapy treatment in a patient with melanoma.</p><p><strong>Case presentation: </strong>A 41-year-old man diagnosed with nodular melanoma of the right torso with axillary lymphadenopathies was treated with dual immunotherapy: nivolumab and ipilimumab. After 24 weeks, patient developed right homolateral hemianopia, and imaging findings correlated with occipital encephalitis. Autoantibodies were not detected. The patient was treated with steroids and exhibited radiological improvement of his encephalitis but maintained his right hemianopia.</p><p><strong>Conclusion: </strong>Neurological side effects of immunotherapy are not very common and range from mild to severe life-threatening symptoms. Previous analyses have shown that combination immunotherapy has a higher risk of side effects than monotherapy. Diagnosis of neurological manifestations is usually made by imaging, mainly brain magnetic resonance imaging or detection of autoantibodies in the CSF. The gold standard treatment is usually corticosteroids or rarely other molecules such as IVIg or monoclonal antibodies. The prognosis is usually favorable.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"206-212"},"PeriodicalIF":0.7,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11805547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report.","authors":"Suthida Suwanvecho, Narongsak Kiatikajornthada, Ployploen Phikulsod, Harit Suwanrusme, Siwanon Jirawatnotai","doi":"10.1159/000542926","DOIUrl":"10.1159/000542926","url":null,"abstract":"<p><strong>Introduction: </strong>Chemotherapy combined with anti-human epidermal growth factor receptor 2 (HER2)-targeted therapy is currently a standard treatment for advanced HER2/HR-positive breast cancer (BC), although evidences showed that HR expression compromised effectiveness of the treatment. While cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy is a key therapy for the BC with HR expression, data on the effectiveness and safety of CDK 4/6 inhibitors combined with trastuzumab and endocrine therapy as a first-line treatment for HER2-positive and HR-positive metastatic BC are limited.</p><p><strong>Case presentation: </strong>Here, we report a case of a 46-year-old premenopausal woman diagnosed with stage 4 HER2/HR-positive invasive ductal carcinoma from both right and left breast with hypermetabolic activities in multiple lymph nodes, adrenal, bone, and skin.</p><p><strong>Interventions: </strong>Due to the patient's refusal to use chemotherapy, she was started on goserelin, abemaciclib, letrozole, and trastuzumab.</p><p><strong>Outcomes: </strong>The patient's symptoms were relieved with near resolution of the primary breast mass and nearly all of the metastatic sites. Metabolic resolution was observed in bone lesions. The disease was under control for 57 weeks. During the treatment, neutropenia (grade 1-2) and anemia (grade 1) occurred, which spontaneously recovered. Additionally, diarrhea improved after symptomatic treatment.</p><p><strong>Conclusion: </strong>We believe that the combination of trastuzumab, hormone suppression, and abemaciclib is a practicable and effective treatment for HER2-positive and HR-positive metastatic BC in premenopausal patients who cannot tolerate the first-line chemotherapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"130-136"},"PeriodicalIF":0.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anesthetic Management of Renal Tumor with Level 3 Inferior Vena Cava Extension at a University Hospital in Vietnam: A Case Report.","authors":"Vu Ton Ngoc Phan, Phat Thanh Tran, Dao Thi Ngoc Nguyen","doi":"10.1159/000542962","DOIUrl":"10.1159/000542962","url":null,"abstract":"<p><strong>Background: </strong>Renal tumors with inferior vena cava (IVC) invasion pose significant challenges for surgical and anesthetic management. This report presents the anesthetic management of a patient with a level 3 IVC-invading renal tumor, emphasizing the complexity and multidisciplinary approach required.</p><p><strong>Case presentation: </strong>A 55-year-old woman with a large left renal tumor causing complete obstruction of the left renal vein and near-total obstruction of the IVC was admitted for surgery. Multidisciplinary planning included a nephrectomy with removal of tumor from the IVC. The patient underwent general anesthesia with extensive hemodynamic monitoring and fluid management to mitigate potential blood loss and cardiovascular instability. The surgery, lasting 5 h, involved successful radical nephrectomy, tumor removal from the IVC, and resection of liver metastases. Postoperative recovery was without complications, and the patient was discharged 7 days.</p><p><strong>Conclusion: </strong>Managing anesthesia for renal tumors with IVC invasion requires careful preoperative planning, invasive monitoring, and multidisciplinary approach.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"120-129"},"PeriodicalIF":0.7,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of Good Syndrome following Recurrent Coronavirus Disease-2019 Infections.","authors":"Moshe Beiser, Joshua K Sabari","doi":"10.1159/000542928","DOIUrl":"10.1159/000542928","url":null,"abstract":"<p><strong>Background: </strong>Good syndrome is defined as the co-occurrence of a thymoma and hypogammaglobulinemia.</p><p><strong>Case: </strong>In this case report, we present a patient who was diagnosed with Good syndrome following recurrent infections with SARS-CoV-2. Of particular note was the patient's repeated presentation despite receiving outpatient treatment with nirmatrelvir-ritonavir. We describe the patient's presentation, diagnosis, and treatment - including robotic thymectomy and passive immunization with IVIG - and report the benefit to quality of life that the patient experienced.</p><p><strong>Conclusion: </strong>This case highlights the importance of quantitative testing of immunoglobulins in patients with known thymomas who present with recurrent infections of SARS-CoV-2.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"107-112"},"PeriodicalIF":0.7,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}